To advance the development of its chronic hepatitis B (CHB) therapies, GSK has entered into a licensing agreement with Janssen Pharmaceuticals for exclusive worldwide rights to JNJ-3989, a small interfering ribonucleic acid (siRNA) therapeutic for CHB, originally in-licensed by Janssen from Arrowhead Pharmaceuticals. GSK plans to evaluate the asset with bepirovirsen, its investigational antisense oligonucleotide, for the treatment of adult non-cirrhotic patients with CHB on nucleos(t)ide analogue (NA) therapy. The deal comes shortly after Janssen announced a series of deal terminations as it streamlines its infectious disease and vaccine portfolio.